This review provides a synopsis of the structural biology underlying constitutive ER activation, the evolutionary dynamics of <i>ESR1</i>-mutant clones detectable through circulating tumor DNA (ctDNA), and the clinical evidence demonstrating that early molecular detection can trigger therapeutic switches that alter disease trajectory. The gene discussed is ESR1; the disease is neoplasm.